Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity

Steroids

Volumn 90, Issue , 2014, Pages 53-59

  Chlebowski, Rowan T ^a   Anderson, Garnet L ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cancer; Estrogen alone; Estrogen plus progestin; Menopausal hormone therapy

Indexed keywords

EID: 84908699100     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.06.001     Document Type: Article

References (82)

1. W. Zhou, and J.M. Slingerland Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy Nat Rev Cancer 14 2014 26 38
2. A. Barzi, A.M. Lenz, M.J. Labonte, and H.J. Lenz Molecular pathways: estrogen pathway in colorectal cancer Clin Cancer Res 19 21 2013 8572 8578
3. J.M. Siegfried, and L.P. Stabile Estrongenic steroid hormones in lung cancer Semin Oncol 41 1 2014 5 16
4. K.K. Leslie, K.W. Thiel, H.D. Reyes, S. Yang, Y. Zhang, and M.J. Carlson The estrogen receptor joins other cancer biomarkers as a predictor of outcome Obstet Gynecol Int 2013 2013 479541
5. M.L. Stefanick Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration Am J Med 188 2005 64S 73S
6. D.C. Smith, R. Prentice, D.J. Thompson, and W.L. Herrmann Association of exogenous estrogen and endometrial carcinoma N Engl J Med 293 1975 1164 1167
7. H.K. Ziel, and W.D. Finkle Increased risk of endometrial carcinoma among users of conjugated estrogens N Engl J Med 293 1975 1167 1171
8. B.A. Briton, and A.S. Felix Menopausal hormone therapy and risk of endometrial cancer J Steroid Biochem Mol Biol 2013 Epub ahead of print
9. V. Beral Breast cancer and hormone replacement therapy in the Million Women Study Lancet 362 2008 419 427
10. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Lancet 350 1997 1047 1059
11. G.A. Colditz Estrogen, estrogen plus progestin therapy, and risk of breast cancer Clin Cancer Res 11 2005 909s 917s
12. W.Y. Chen, J.E. Manson, S.E. Hankinson, B. Rosner, M.D. Holmes, and W.C. Willett Unopposed estrogen therapy and the risk of invasive breast cancer Arch Intern Med 166 9 2006 1027 1032
13. K. Holli, J. Isola, and J. Cuzick Low biologic aggressiveness in breast cancer in women using hormone replacement therapy J Clin Oncol 16 1998 3115 3120
14. W.Y. Chen Exogenous and endogenous hormones and breast cancer Best Pract Res Clin Endocrinol Metab 22 4 2008 573 585
15. U. Salagame, K. Canfell, and E. Banks An epidemiological overview of the relationship between hormone replacement therapy and breast cancer Expert Rev Endocrinol Metab 6 2011 397 409
16. H.D. Nelson, L.L. Numphrey, P. Nygren, S.M. Teutsch, and J.D. Allan Postmenopausal hormone replacement therapy: scientific review JAMA 288 7 2002 872 881
17. G.A. Greendale, and H.L. Judd The menopause: health implications and clinical management J Am Geriatr Soc 41 1993 426 436
18. M.J. Stampfer, G.A. Colditz, W.C. Willet, J.E. Manson, B. Rosner, and F.E. Speizer Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurse's Health Study N Engl J Med 325 1991 756 762
19. L.E. Nachtigall, R.H. Nachtigall, R.D. Nachtigall, and E.M. Beckman Estrogen replacement therapy I: a 10-year prospective study in the relationship of osteoporosis Obstet Gynecol 53 3 1979 277 281
20. W.L. McBee, M.E. Dailey, E. Dugan, and S.A. Shumaker Hormone replacement therapy and other potential treatments for dementias Endocrinol Metab Clin North Am 26 1997 329 345
21. A.L. Hersh, M.L. Stefanick, and R.S. Stafford National use of menopausal hormone therapy: annual trends and response to recent evidence JAMA 291 2004 47 53
22. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
23. G.L. Anderson, M. Limacher, R. Assaf, T. Bassford, S.A. Beresford, and H. Black Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
24. G.L. Anderson, J. Manson, R. Wallace, B. Lund, D. Hall, and S. Davis Implementation of the Women's Health Initiative study design Ann Epidemiol 13 2003 S5 17
25. R.T. Chlebowski, S.L. Hendrix, R.D. Langer, M.L. Stefanick, M. Gass, and D. Lane Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial JAMA 289 2003 3243 3253
26. R.T. Chlebowski, G.L. Anderson, M. Gass, D.S. Lane, A.K. Aragaki, and L.H. Kuller Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women JAMA 304 2010 1684 1692
27. R.T. Chlebowski, G.L. Anderson, M. Pettinger, D. Lane, R.D. Langer, and M.A. Gilligan Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy Arch Intern Med 168 2008 370 377
28. M.M. Joffe, C. Byrne, and G.A. Colditz Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias Epidemiology 12 2001 429 438
29. S. Hofvind, R. Sorum, T. Haldorsen, and F. Langmark Incidence of breast cancer before and after implementation of mammography screening Tidsskr Nor Laegeforen 126 2006 2935 2938
30. H. Sihto, J. Lundin, T. Lehtimaki, M. Sarlomo-Rikala, R. Butzow, and K. Holli Molecular subtypes of breast cancers detected in mammography screening and outside of screening Clin Cancer Res 14 2008 4103 4110
31. R.L. Prentice, R.T. Chlebowski, M.L. Stefanick, J.E. Manson, M. Pettinger, and S.L. Hendrix Estrogen plus progestin therapy and breast cancer in recently postmenopausal women Am J Epidemiol 167 2008 1207 1216
32. A. Fournier, S. Mesrine, M.C. Boutron-Ruault, and F. Clavel-Chapelon Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27 2009 5138 5143
33. V. Beral, G. Reeves, D. Bull, and J. Green Breast cancer risk in relation to the interval between menopause and starting hormone therapy J Natl Cancer Inst 103 2011 1 10
34. R.T. Chlebowski, and G.L. Anderson The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment J Natl Cancer Inst 103 2011 284 285
35. M.L. Stefanick, G.L. Anderson, K.L. Margolis, S.L. Hendrix, R.J. Rodabough, and E.D. Paskett Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy JAMA 295 2006 647 657
36. A.Z. Lacroix, R.T. Chlebowski, J.E. Manson, A.K. Aragaki, K.C. Johnson, and L. Martin Health risks and benefits 5 years after stopping randomized treatment with conjugated equine estrogens in postmenopausal women with prior hysterectomy JAMA 305 2011 1305 1314
37. G.L. Anderson, R.T. Chlebowski, A. Aragaki, J. Manson, T. Roham, and L. Kuller Oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy extended follow-up of the Women's Health Initiative randomized trial Lancet Oncol 13 5 2012 476 486
38. J.A. Manson, R.T. Chlebowski, M.L. Stefanick, A.K. Aragaki, B. Howard, and J. Rossouw The Women's Health Initiative hormone therapy trials: update and overview of health outcomes during the intervention and post-stopping phases JAMA 310 3 2013 1 17
39. R.L. Prentice, R.T. Chlebowski, M.L. Stefanick, J.E. Manson, R.D. Langer, and M. Pettinger Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study Am J Epidemiol 167 2008 1407 1415
40. I. Obiorah, and V.C. Jordan The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortality Menopause 20 4 2013 372 382
41. A. Howell, and J. Cuzick Oestrogen and breast cancer: results from the WHI trial Lancet Oncol 13 5 2012 437 438
42. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, and W.M. Cronin Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast Cancer and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
43. E. Cordina-Duverger, T. Truong, A. Anger, M. Sanchez, P. Arveux, and P. Kerbrat Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France PLos ONE 8 11 2013 e78016
44. K. Bakken, A. Fournier, E. Lund, M. Waaseth, V. Dumeaux, and F. clavel-Chapelon Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition Int J Cancer 128 2011 144 156
45. R.J. Santen Risk of breast cancer with progestins: critical assessment of current data Steroids 68 2003 953 964
46. A. Fournier, F. Berrino, and F. Clavel-Chapelon Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N-EPIC cohort study Breast Cancer Res Treat 107 2008 103 111
47. N.E. Allen, K.K. Tsilidis, T.J. Key, L. Dossus, R. Kaaks, and E. Lund Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women. European Prospective Investigation into Cancer and Nutrition Am J Epidemiol 172 2010 1394 1403
48. A. McTiernan, C.F. Martin, J.D. Peck, A.K. Aragaki, R.T. Chlebowski, and E.D. Pisano Estrogen plus progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial J Natl Cancer Inst 97 2005 1366 1376
49. A. McTiernan, R.T. Chlebowski, C. Martin, J.D. Peck, A. Aragaki, and Ed. Pisano Conjugated equine estrogen influence on mammographic density in postmenopausal women in a sub-study of the Women's Health Initiative randomized trial J Clin Oncol 27 2009 6135
50. R.T. Chlebowski, G.L. Anderson, J.E. Manson, M. Pettinger, S. Yasmeen, and D. Lane Estrogen alone in postmenopausal women and breast cancer detection by means by mammography and breast biopsy J Clin Oncol 28 2010 2690 2697
51. T.E. Rohan, A. Negassa, R.T. Chlebowski, L. Habel, A. McTiernan, and M. Ginsberg Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial J Natl Cancer Inst 100 8 2008 563 571
52. T.E. Rohan, A. Negassa, R.T. Chlebowski, N.L. Lasser, A. McTiernan, and R.S. Schenken Estrogen plus progestin and risk of benign proliferative breast disease Cancer Epidemiol Biomarkers Prev 17 9 2008 2337 2343
53. P.E. Goss, J.N. Ingle, J. Ales-Martinez, A. Cheung, R.T. Chlebowski, and J. Wactawski-Wende Exemestane for breast-cancer prevention in postmenopausal women N Engl J Med 364 25 2011 2381 2391
54. J. Cuzick, I. Sestak, J.F. Forbes, M. Dowsett, J. Knox, and S. Cawthorn Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Lancet 383 9922 2013 1041 1048
55. V.C. Jordan, and L.G. Ford Paradoxical clinical effects of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis Cancer Prev Res 4 2011 633 637
56. A.K. Dunbier, L.A. Martin, and M. Dowsett New and translational perspective of oestrogen deprivation in breast cancer Mol Cell Endocrinol 340 2 2011 137 141
57. R.J. Santen, R.X. Song, Z. Zhang, R. Kumar, M.H. Jeng, and S. Masamura Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment J Steroid Biochem Mol Biol 95 2005 155 165
58. S. Zhao, R.T. Chlebowski, G.L. Anderson, L.H. Kuller, J.E. Manson, and M. Gass Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects Breast Cancer Res 16 2014 R30
59. G. Heiss, R. Wallace, G.L. Anderson, A. Aragaki, S.A. Beresford, and R. Brzyski Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin JAMA 299 2008 1036 1045
60. R.T. Chlebowski, A.G. Schwartz, H. Wakelee, G.L. Anderson, M.L. Stefanick, and J.E. Manson Estrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomized controlled trial Lancet 374 2009 1243 1251
61. R.T. Chlebowski, G.L. Anderson, J.E. Manson, A.G. Schwartz, H. Wakelee, and M. Gass Lung cancer among postmenopausal women treated with estrogen alone in the Women's Health Initiative randomized trial J Natl Cancer Inst 102 2010 1413 1421
62. M.R. Palomares, J.W. Sayre, K.C. Shekar, L.M. Lillington, and R.T. Chlebowski Gender influence on weight-loss pattern and survival of non-small cell lung carcinoma patients Cancer 78 1996 2119 2126
63. S. Harichand-Herdt, and S.S. Ramalingam Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women Semin Oncol 36 2009 572 580
64. S.E. Olivo-Marston, L.E. Mechanic, S. Mollerup, E.D. Bowman, A.T. Remaley, and M.R. Forman Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifers of non-small-cell lung cancer survival in both men and women Carcinogenesis 31 2010 1778 1786
65. D.C. Marquez-Garban, H.W. Chen, L. Goodglick, M.C. Fishbein, and R.J. Pietras Targeting aromatase and estrogen signaling in human non-small cell lung cancer Ann NY Acad Sci 115 2009 194 205
66. F. Grodstein, P.A. Newcomb, and M.J. Stampfer Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis Am J Med 106 1999 574 582
67. M.S. Simon, R.T. Chlebowski, J. Wactawski-Wende, K.C. Johnson, A. Muskovitz, and I. Kato Estrogen plus progestin and colorectal cancer incidence and mortality J Clin Oncol 30 32 2012 3983 3990
68. R.T. Chlebowski, J. Wactawski-Wende, C. Ritenbaugh, F.A. Hubbell, J. Ascensao, and R.J. Rodabough Estrogen plus progestin and colorectal cancer in postmenopausal women N Engl J Med 350 2004 991 1004
69. R. Siegel, C. Desantis, and A. Jemal Colorectal cancer statistics, 2014 CA Cancer J Clin 64 2 2014 104 117
70. C. Ritenbaugh, J.L. Stanford, L. Wu, J.M. Shikany, R.E. Schoen, and M.L. Stefanick Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial Cancer Epidemiol Biomarkers Prev 17 2008 2609 2618
71. V. Beral, D. Bull, G. Reeves Million Women Study Collaborators Endometrial cancer and hormone-replacement therapy in the Million Women Study Lancet 365 2005 1543 1551
72. S. Karageorgi, S.E. Hankinson, P. Kraft, and I. De Vivo Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004 Int J Cancer 126 2010 208 216
73. G.L. Anderson, H.L. Judd, A.M. Kaunitz, D.H. Barad, S.A. Beresford, and M. Pettinger Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women's Health Initiative randomized trial JAMA 290 2003 1739 1748
74. K. Zbuk, Q. Sun, R. Cong, H. Gu, N. Tang, and L. Yang Hormone replacement therapy and ovarian cancer risk: a meta-analysis Gynecol Oncol 108 3 2008 641 651
75. S.A. Tsai, M.L. Stefanick, and R.S. Stafford Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009 Menopause 18 2011 385 392
76. C.A. Clarke, S.L. Glasser, C.S. Uratsu, J.V. Selby, L.H. Kushi, and L.J. Herrinton Recent declines in hormone therapy utilization and breast cancer incidence. clinical and population-based evidence J Clin Oncol 24 33 2006 e49 e50
77. P.M. Ravdin, K.A. Cronin, B. Howlander, C.D. Berg, R.T. Chlebowski, and E.J. Fewer The decrease in breast cancer incidence in 2003 in the United States N Engl J Med 356 16 2007 1670 1674
78. R.T. Chlebowski, L.H. Kuller, R.L. Prentice, M.L. Stefanick, J.E. Manson, and M. Gass Breast cancer after estrogen plus progestin use in postmenopausal women N Engl J Med 360 2009 573 587
79. K. Zbuk, and S.S. Anand Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries J Epidemiol Community Health 66 2012 1 7
80. P. Wartko, M.E. Sherman, H.P. Yang, A.S. Felix, L.A. Brinton, and B. Trabert Recent changes in endometrial cancer trends among menopausal-age US women Cancer Epidemiol 37 4 2013 374 377
81. G.G. Nahum, H. Stanislaw, and J.A. Simon Stopping menopausal hormone therapy: If breast cancer really decreased, why did colorectal cancer not increase? Maturitas 71 4 2012 354 359
82. E.G. Nabel The Women's Health Initiative - a victory for women and their health JAMA 310 13 2013 1349 1350